Jiangmen Hengjian Pharmaceutical Co. Ltd.

Main purpose: Using pharmacokinetic parameters as the primary endpoint evaluation index, compare the pharmacokinetic behavior of the test preparation norfloxacin capsule (specification: 0.1g, license holder: Guangdong Hengjian Pharmaceutical Co., Ltd.) and the reference preparation norfloxacin tablet (specification: 0.1g, license holder: Xinglin Pharmaceutical Co., Ltd., trade name: BACCIDAL®) in healthy subjects after oral administration in the fasting state, and evaluate the bioequivalence of the two preparations. Secondary purpose: Observe the safety of the test preparation norfloxacin capsule and the reference preparation norfloxacin tablet in healthy subjects.

To investigate the pharmacokinetic characteristics of healthy subjects after a single application of one loxoprofen sodium gel patch produced by Guangdong Hengjian Pharmaceutical Co., Ltd. (test preparation T, specification: 100 mg/patch) or one loxoprofen sodium gel patch certified by LEAD CHEMICAL CO., LTD. (reference preparation R, trade name: LOXONIN PAP®, specification: 100 mg/patch), and to evaluate the bioequivalence and safety of the two preparations. At the same time, the adhesion and skin irritation of the two preparations were investigated to provide a basis for the registration application of the test preparation.

The main purpose of the study is to use Lupin LTD's licensed cefprozil tablets (calculated as C18H19N3O5S, 250mg) as the reference preparation and Guangdong Hengjian Pharmaceutical Co., Ltd.'s cefprozil tablets (calculated as C18H19N3O5S, 250mg) as the test preparation, and to evaluate the bioequivalence of the two preparations in the fasting and fed state through a single-center, randomized, open, single-dose, two-period, double-crossover clinical study. Secondary purpose of the study: To observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.